What question did this study set out to answer?

To develop a next-generation multi-payload conjugate that overcomes the limitations of current antibody-drug conjugates in treating cancer.

Abstract PS4-06-12: Dual-payload TROP2 targeted antibody drug conjugate: Multi-Payload Conjugates™ deliver orthogonal mechanisms of cell killing

View Full Paper

Ask AI

Bookmark

To develop a next-generation multi-payload conjugate that overcomes the limitations of current antibody-drug conjugates in treating cancer.
Development of dual-payload ADCs using a selective conjugation platform.
Testing in TROP2 expressing xenograft models including CDX and PDX models.
Evaluation of safety and tolerability in non-human primate toxicology trials.
CATB-101 shows superior inhibition of tumor growth compared to existing ADCs.
Demonstrated full tumor elimination in various xenograft models.
Catena’s MPCs™ exhibit enhanced safety profiles in non-human primate studies.

No takes yet. Share an insight, caveat, or question.

This research demonstrates the effectiveness of a dual-payload therapy in eliminating tumors, indicating a new approach to antibody-drug conjugates.

Lobba et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This research demonstrates the effectiveness of a dual-payload therapy in eliminating tumors, indicating a new approach to antibody-drug conjugates.